Mini Review
Accepted on 22 Nov 2024
Fyn, an important molecule in the brain, is a potential therapeutic target for brain tumours
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1485919
Type at least 3 characters
2,611 articles
Articles
Original Research
Accepted on 21 Nov 2024
Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1464852
Original Research
Accepted on 21 Nov 2024
Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1503154
Review
Accepted on 21 Nov 2024
Recent Advances in Cell Membrane-Coated Porphyrin-Based Nanoscale MOFs for Enhanced Photodynamic Therapy
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1505212
Review
Accepted on 21 Nov 2024
NGF-Mediated Crosstalk: Unraveling the Influence of Metabolic deregulation on the Interplay Between Neural and Pancreatic Cancer Cells and its impact on Patient Outcomes
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1499414
Systematic Review
Published on 21 Nov 2024
Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1446403
- 211 views
Original Research
Published on 21 Nov 2024
The role of epigenetic regulation in pancreatic ductal adenocarcinoma progression and drug response: an integrative genomic and pharmacological prognostic prediction model
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1498031
- 140 views
Case Report
Accepted on 20 Nov 2024
Pemigatinib combined with immunotherapy and stereotactic body radiation therapy for FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis: a case report
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1509891
Original Research
Accepted on 20 Nov 2024
Polyketides and Alkaloids from the Fungus Aspergillus Fumigatus YB4-17 and Ent-Fumiquinazoline J Induce Apoptosis, Paraptosis in Human Hepatoma HepG2 Cells
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1487977
Review
Accepted on 19 Nov 2024
Application of nanotechnology in the treatment of hepatocellular carcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1438819
Review
Accepted on 19 Nov 2024
Targeting cuproptosis with nano material: New way to enhancing the efficacy of immunotherapy in colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1451067
Review
Accepted on 19 Nov 2024
Plant protein-derived anti-breast cancer peptides: sources, therapeutic approaches, mechanisms, and nanoparticle design
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1468977
Original Research
Published on 19 Nov 2024
Targeting autophagy: polydatin’s role in inducing cell death in AML
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1470217
- 134 views
Original Research
Published on 19 Nov 2024
Impact of camel milk lactoferrin peptides against breast cancer cells: in silico and in vitro study
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1425504
- 299 views
Editorial
Accepted on 18 Nov 2024
Editorial: Exploring Immunotherapy Targets and Strategies for Cancer: A Multi-Omics Perspective
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1506444
Editorial
Accepted on 18 Nov 2024
Editorial: Utilizing Omics Strategies to Discover New Drug Targets for Cancers
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1526976